Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17253862 | APPLICATION OF GENE PROFILE FOR CELLS ISOLATED USING FRESH-TRACER | December 2020 | May 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17254108 | BIOLOGICAL SAMPLE WARMING METHOD, BIOLOGICAL SAMPLE WARMING VESSEL, AND KIT FOR WARMING BIOLOGICAL SAMPLE | December 2020 | February 2025 | Abandon | 50 | 0 | 1 | No | No |
| 16972834 | PRODUCTION METHOD FOR NEURON-LIKE CELLS | December 2020 | May 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 17058279 | CRYOPRESERVATION OF TISSUES AND ORGANS | November 2020 | May 2024 | Allow | 41 | 1 | 1 | No | No |
| 17050784 | GENE THERAPY FOR CNS DEGENERATION | October 2020 | April 2025 | Allow | 53 | 1 | 1 | Yes | No |
| 17049372 | DENTAL PULP STEM CELLS AND USES THEREOF | October 2020 | May 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17048707 | METHODS FOR MEASURING AND STABILIZING STAT3 INHIBITORS | October 2020 | March 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17044680 | REPROGRAMMING VECTORS | October 2020 | September 2024 | Allow | 48 | 1 | 1 | No | No |
| 17025821 | METHOD FOR THREE-DIMENSIONALLY CULTURING PLURIPOTENT STEM CELL | September 2020 | December 2023 | Abandon | 39 | 1 | 0 | No | No |
| 17006138 | METHOD OF CULTURING CELL, METHOD OF MANUFACTURING CELL SUPPORT COMPLEX, CULTURED CELL, AND CELL SUPPORT COMPLEX | August 2020 | September 2024 | Allow | 49 | 3 | 1 | Yes | No |
| 17003799 | SUPER ENHANCER FOR DRIVING PLURIPOTENCY NETWORK AND STEMNESS CIRCUITRY | August 2020 | September 2023 | Allow | 37 | 2 | 0 | Yes | No |
| 16991522 | METHODS OF VENTRAL RECEPTACLE COMPRESSION TECHNIQUE FOR SCORING MATED STATUS IN INSECTS INCLUDING FRUIT FLIES | August 2020 | February 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 16936330 | METHODS FOR TELOMERE LENGTH AND GENOMIC DNA QUALITY CONTROL ANALYSIS IN PLURIPOTENT STEM CELLS | July 2020 | October 2024 | Abandon | 51 | 1 | 1 | No | No |
| 16924056 | RECOMBINANT PRODUCTION METHOD | July 2020 | January 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16912973 | SILOXANE POLYMER-BASED CANCER STEM CELL PREPARATION METHOD | June 2020 | May 2025 | Abandon | 59 | 4 | 1 | No | No |
| 16767383 | COMPOSITION AND METHOD FOR CULTIVATION, EXPANSION, PRESERVATION AND/OR CELL PRETREATMENT | May 2020 | June 2024 | Allow | 48 | 2 | 1 | No | No |
| 16838511 | MICROPATTERNED HYDROGEL FOR CELL CULTURES | April 2020 | July 2024 | Allow | 51 | 3 | 1 | No | No |
| 16640403 | METHODS FOR INDUCING HEMATOPOIETIC STEM CELL SPECIFICITY | February 2020 | May 2024 | Allow | 51 | 3 | 1 | No | No |
| 16635861 | COMPOSITIONS AND METHODS FOR TARGETING MASAS TO TREAT CANCERS WITH SPLICEOSOME MUTATIONS | January 2020 | May 2024 | Allow | 52 | 3 | 1 | No | No |
| 16623605 | METHOD FOR KNOCKING OUT TARGET GENE IN T CELL IN VITRO AND crRNA USED IN THE METHOD | December 2019 | April 2023 | Abandon | 40 | 0 | 1 | No | No |
| 16621707 | METHODS OF PRODUCING BIOENGINEERED NEURONAL ORGANOIDS (BENOS) AND USES THEREOF | December 2019 | May 2023 | Allow | 41 | 1 | 1 | No | No |
| 16620655 | METHOD FOR TREATING DILATED CARDIOMYOPATHY | December 2019 | April 2024 | Abandon | 52 | 3 | 1 | No | No |
| 16702755 | METHOD FOR INCREASING THE PROPORTION OF DESIRED CELLS FROM INDUCED PLURIPOTENT STEM CELLS | December 2019 | May 2024 | Allow | 53 | 4 | 0 | Yes | No |
| 16606240 | RECOMBINATION ACTIVATING GENE (RAG) INDUCED V(D)J GENE TARGETING | October 2019 | March 2024 | Allow | 53 | 1 | 2 | No | No |
| 16570327 | METHOD FOR SEPARATING MEGAKARYOCYTES AND PLATELETS, AND PLATELET SEPARATION KIT | September 2019 | March 2024 | Abandon | 54 | 0 | 1 | No | No |
| 16489142 | THREE-DIMENSIONAL TISSUE STRUCTURES | August 2019 | June 2023 | Abandon | 45 | 1 | 1 | No | No |
| 16533300 | IMMERSION DEPOSITION METHODS AND COMPOSITIONS FOR USE IN THE SAME | August 2019 | January 2024 | Allow | 54 | 3 | 0 | Yes | No |
| 16088367 | COMPOSITIONS AND METHODS FOR USING SMALL MOBILE STEM CELLS | September 2018 | July 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 15743248 | NON-HUMAN ANIMAL HAVING HUMAN CD3 GENE SUBSTITUTED FOR ENDOGENOUS CD3 GENE | January 2018 | January 2023 | Allow | 60 | 4 | 1 | No | No |
| 15519742 | BIPARTITE AND TRIPARTITE SIGNALING IMMUNE CELLS | April 2017 | September 2023 | Abandon | 60 | 7 | 1 | No | No |
| 14922110 | CORTICAL INTERNEURONS AND OTHER NEURONAL CELLS PRODUCED BY THE DIRECTED DIFFERENTIATION OF PLURIPOTENT AND MULTIPOTENT CELLS | October 2015 | January 2023 | Allow | 60 | 6 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner CONTES DE JESUS, MAYTEE MARIE works in Art Unit 1632 and has examined 31 patent applications in our dataset. With an allowance rate of 58.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.
Examiner CONTES DE JESUS, MAYTEE MARIE's allowance rate of 58.1% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CONTES DE JESUS, MAYTEE MARIE receive 2.10 office actions before reaching final disposition. This places the examiner in the 52% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CONTES DE JESUS, MAYTEE MARIE is 51 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +59.1% benefit to allowance rate for applications examined by CONTES DE JESUS, MAYTEE MARIE. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 29.5% of applications are subsequently allowed. This success rate is in the 59% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 14.3% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 133.3% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 11.1% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.